PMID- 27800020
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 1756-2856 (Print)
IS  - 1756-2864 (Electronic)
IS  - 1756-2856 (Linking)
VI  - 9
IP  - 6
DP  - 2016 Nov
TI  - Two-year real-world experience with perampanel in patients with refractory focal 
      epilepsy: Austrian data.
PG  - 445-453
AB  - BACKGROUND: The aim of this study was to analyse registry data of seizure outcome 
      and adverse events (AEs) for perampanel as add-on therapy in patients with focal 
      epilepsy since its approval in 2012 for adjunctive treatment of focal epilepsy in 
      patients ⩾12 years. METHOD: A retrospective 2-year chart review of all patients 
      receiving perampanel was carried out. RESULTS: A total of 122 patients received 
      perampanel [median treatment length: 20.1 (range: 3.4-26.8) months]; 71 (58%) 
      remained on treatment at last follow up. Overall, 33 patients (27%) were 
      seizure-free for ⩾3 months at last follow up; of these, eight were seizure free 
      for ⩾3 times the longest interictal interval before perampanel therapy; 18 (15%) 
      had reduced seizure frequency ⩾50%. A total of 58 (47%) had an AE and 34 (28%) 
      withdrew from treatment because of AEs. AEs included dizziness (33%), fatigue 
      (12%), psychiatric symptoms (8%), cognitive deficits (7%), speech problems (5%), 
      nausea (4%) and gait problems (4%). AEs subsided in 17/18 patients (94%) 
      following a 2 mg dose reduction. A total of 43 (35%) took a concomitant enzyme 
      inducer. Patients not taking enzyme inducers were more likely to be seizure free 
      (p = 0.002); there were no other between-group differences. CONCLUSIONS: 
      Perampanel was well tolerated and improved seizure control in 42% of patients 
      (50- 100% reduction), with higher rates in those not receiving a concomitant 
      enzyme inducer. AEs, particularly dizziness, were common but often disappeared 
      with a slight dose reduction. The results are consistent with those from 
      randomized controlled trials.
FAU - Rohracher, Alexandra
AU  - Rohracher A
AD  - Department of Neurology, Christian Doppler Medical Klinik of the Paracelsus 
      Medical University Salzburg, Ignaz-Harrer-Strasse 79, A-5020 Salzburg, Austria.
FAU - Kalss, Gudrun
AU  - Kalss G
AD  - Department of Neurology, Christian Doppler Medical Klinik of the Paracelsus 
      Medical University Salzburg, Salzburg, Austria.
FAU - Leitinger, Markus
AU  - Leitinger M
AD  - Department of Neurology, Christian Doppler Medical Klinik of the Paracelsus 
      Medical University Salzburg, Salzburg, Austria.
FAU - Granbichler, Claudia
AU  - Granbichler C
AD  - Department of Neurology, Christian Doppler Medical Klinik of the Paracelsus 
      Medical University Salzburg, Salzburg, Austria.
FAU - Deak, Ildiko
AU  - Deak I
AD  - Department of Neurology, Christian Doppler Medical Klinik of the Paracelsus 
      Medical University Salzburg, Salzburg, Austria.
FAU - Dobesberger, Judith
AU  - Dobesberger J
AD  - Department of Neurology, Christian Doppler Medical Klinik of the Paracelsus 
      Medical University Salzburg, Salzburg, Austria.
FAU - Kuchukhidze, Giorgi
AU  - Kuchukhidze G
AD  - Department of Neurology, Christian Doppler Medical Klinik of the Paracelsus 
      Medical University Salzburg, Salzburg, Austria.
FAU - Thomschewski, Aljoscha
AU  - Thomschewski A
AD  - Department of Neurology, Christian Doppler Medical Klinik of the Paracelsus 
      Medical University Salzburg, Salzburg, Austria.
FAU - Hofler, Julia
AU  - Hofler J
AD  - Department of Neurology, Christian Doppler Medical Klinik of the Paracelsus 
      Medical University Salzburg, Salzburg, Austria.
FAU - Trinka, Eugen
AU  - Trinka E
AD  - Department of Neurology, Christian Doppler Medical Klinik of the Paracelsus 
      Medical University Salzburg, Salzburg, Austria.
LA  - eng
PT  - Journal Article
DEP - 20160901
PL  - England
TA  - Ther Adv Neurol Disord
JT  - Therapeutic advances in neurological disorders
JID - 101480242
PMC - PMC5066528
OTO - NOTNLM
OT  - clinical experience
OT  - efficacy
OT  - focal epilepsy
OT  - perampanel
OT  - tolerability
COIS- The author(s) declared the following potential conflicts of interest with respect 
      to the research, authorship, and/or publication of this article: A. Rohracher has 
      acted as a paid consultant for Neuroconsult and received travel support from 
      Eisai. J. Dobesberger has received honoraria from UCB Pharma, Gerot Lanach Pharma 
      GmbH, Eisai, and GlaxoSmithKline and received travel support from UCB Pharma, 
      Gerot Lanach Pharma GmbH, Eisai, GlaxoSmithKline and Neurodata Handels 
      GmbH/Micromed Austria. C. A. Granbichler received travel support from Cyberonics 
      and Eisai. J. Hofler has received speaker honoraria from UCB and travel support 
      from UCB and Eisai. M. Leitinger received travel support from Medtronic. G. Kalss 
      received travel support from UCB. I. Deak, G. Kuchukhidze and A. Thomschewski 
      have nothing to disclose. E. Trinka has acted as a paid consultant for Eisai, 
      Ever Neuropharma, Biogen Idec, Medtronics, Bial, Sanofi-Aventis, Takeda, SAGE, 
      Genzyme and UCB. He has received research funding from UCB, Biogen-Idec, 
      Sanofi-Aventis, Genzyme, FWF, Jubilaumsfond der Osterreichischen Nationalbank and 
      Red Bull as well as speakers' honoraria from Bial, Eisai, Ever Neuropharma, GL 
      Lannacher, Genzyme, Biogen, Glaxo Smith Kline, Sanofi-Aventis, Boehringer, 
      Viropharma, Actavis and UCB.
EDAT- 2016/11/02 06:00
MHDA- 2016/11/02 06:01
PMCR- 2016/11/01
CRDT- 2016/11/02 06:00
PHST- 2016/11/02 06:00 [pubmed]
PHST- 2016/11/02 06:01 [medline]
PHST- 2016/11/02 06:00 [entrez]
PHST- 2016/11/01 00:00 [pmc-release]
AID - 10.1177_1756285616661115 [pii]
AID - 10.1177/1756285616661115 [doi]
PST - ppublish
SO  - Ther Adv Neurol Disord. 2016 Nov;9(6):445-453. doi: 10.1177/1756285616661115. 
      Epub 2016 Sep 1.